Incretin-Based Drugs Market Expansion Outlook: $36.7 Billion by 2029 Forecast

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Incretin-Based Drugs Market By 2029?

The incretin-based drugs market has experienced substantial growth in recent years. Its value is expected to rise from $25.89 billion in 2024 to $27.83 billion in 2025, at a compound annual growth rate (CAGR) of 7.5%. This historical expansion can be attributed to several factors, including the increasing global prevalence of type 2 diabetes, the introduction of GLP-1 receptor agonists such as exenatide and liraglutide, considerable investments in research and development, advantageous regulatory approvals for DPP-4 and GLP-1 drugs, a shift away from insulin and sulfonylureas towards newer classes of medication, and the availability of once-weekly injectable formulations.

The incretin-based drugs market size is projected to experience substantial expansion over the upcoming years. This market is set to reach a valuation of $36.7 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the projection period stems from several factors, including the rising acceptance of fixed-dose combination treatments, an increased emphasis on weight control and diabetes associated with obesity, advancements in personalized medicine and companion diagnostics, a heightened need for less invasive drug delivery methods, and an expanding elderly demographic facing a greater prevalence of comorbidities. Key trends anticipated during this forecast encompass the incorporation of incretin pharmaceuticals into strategies for obesity management, the emergence of dual and triple agonists designed to improve metabolic results, the fusion of digital health solutions with incretin therapies for tailored oversight, the increasing prevalence of combination therapies over monotherapy for sophisticated diabetes regulation, and an emphasis on long-acting weekly injections to ease the frequency of administration.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

What Are The Key Drivers Of Growth In The Incretin-Based Drugs Market?

The increasing occurrence of type 2 diabetes mellitus is anticipated to drive the expansion of the incretin-based drugs market moving ahead. This condition is a persistent metabolic ailment marked by the body’s resistance to insulin and reduced insulin production, resulting in elevated blood sugar levels. Its widespread occurrence stems from unhealthy eating habits and lack of physical activity, which contribute to insulin resistance, thereby diminishing the body’s capacity to manage blood sugar effectively. Incretin-based drugs address type 2 diabetes by stimulating insulin secretion following meals and decreasing glucagon output, which assists in lowering blood sugar. Additionally, these medications postpone gastric emptying and suppress hunger, facilitating better glucose management and weight reduction. For example, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, approximately 549,000 additional individuals in England were at risk of developing type 2 diabetes, bringing the total number with pre-diabetes to more than 3.6 million, marking a nearly 20% increase from 2022. Consequently, the growing incidence of type 2 diabetes mellitus is fueling the expansion of the incretin-based drugs market.

How Is The Incretin-Based Drugs Market Segmented?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide, Albiglutide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Are The Latest Industry Trends Transforming The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are increasingly focusing on the development of generic drug versions to offer more effective and patient-friendly treatment options for type 2 diabetes. A generic drug is a medication that possesses the same active ingredients, strength, dosage form, and route of administration as a brand-name drug, but is commercially sold under its chemical designation without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, within the United States. This product received Food and Drug Administration (FDA) approval. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, thereby furnishing a new, more affordable option amidst ongoing shortages of GLP-1 medications.

Which Major Firms Are Strengthening Their Position In The Incretin-Based Drugs Industry?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Incretin-Based Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2025, By The Business Research Company

Null 2025

NULL

Hybrid Valve Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hybrid-valve-global-market-report

Hybrid Composites Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hybrid-composites-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795